Query II

(FILE 'REGISTRY' ENTERED AT 15:16:49 ON 29 JUL 2003)
L1 1 SEA ABB=ON PLU=ON ".ALPHA.-LIPOIC ACID"/CN
L2 1 SEA ABB=ON PLU=ON HUPERZINE A/CN

FILE 'HCAPLUS' ENTERED AT 15:17:09 ON 29 JUL 2003
L3 8 SEA ABB=ON PLU=ON B VITAMIN AND (L1 OR ALPHA LIPOIC OR ALA OR THIOCTIC)
L4 0 SEA ABB=ON PLU=ON L3 AND (L2 OR HUPERZINE A)

FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH, JICST-EPLUS, JAPIO' ENTERED AT 15:18:15 ON 29 JUL 2003
L5 1 SEA ABB=ON PLU=ON L4

L5 ANSWER 1 OF 1 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: 2003-340969 [32] WPIDS
DOC. NO. CPI: C2003-089364
TITLE: Composition comprises adenosine triphosphate and creatine phosphate synthesis promoter, antioxidant, agents for maintaining membrane and neurotransmitter function, cortisol down regulator, apoptosis activation suppresser.
DERWENT CLASS: B05
INVENTOR(S): MCCLEARY, E L
PATENT ASSIGNEE(S): (MCCL-I) MCCLEARY E L
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2002182196	A1	20021205	(200332)*		16

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2002182196	A1	US 2001-837562	20010419

PRIORITY APPLN. INFO: US 2001-837562 20010419
AN 2003-340969 [32] WPIDS
AB US2002182196 A UPAB: 20030522
NOVELTY - A composition (C1) comprises: at least one of
(1) adenosine triphosphate (ATP) and/or creatine phosphate synthesis promoter;
(2) an antioxidant for scavenging free radicals in at least one pathway;
(3) an agent for:
(a) normalizing or maintaining membrane function and structure;
(b) normalizing or maintaining neurotransmitter function;
(c) down-regulating cortisol action; and
(d) suppressing activation of apoptotic pathways.
ACTIVITY - Neuroprotective; Nootropic; Tranquilizer; Vulnerary; Immunosuppressive; Vasotropic; Hypotensive; Antiinflammatory; Cerebroprotective; Antimicrobial.
MECHANISM OF ACTION - None given.
USE - For normalizing impaired or deteriorating neurological function in the body of a human (claimed) and as a nutritional supplement. Also useful for treating memory deterioration,

behavioral problems, attention deficit disorder, attention deficit hyperactivity disorder, other inattention and hyperactivity syndromes, dementia, cognitive decline of multiple etiologies, genetic disorders (e.g. Downs syndrome, fragile X syndrome, etc.), central nervous system (CNS) trauma, intoxications (acute or chronic), poisoning, auto-immune mechanisms, anoxic-ischemic conditions, neurodegenerative disorders, metabolic afflictions of the nervous system, vascular insults, hypertensive encephalopathy, rheological disorders, demyelination, cerebral edema, inflammatory neuronal conditions, learning disabilities, impulsive behavior, specific emotional or mood problems, difficulty functioning under pressure, various latrogenic conditions, infections, eleptogenic foci and congenital brain malformations.

ADVANTAGE - (C1) provides a comprehensive holistic approach for the treatment of neurological abnormalities. (C1) improves symptomalogy and also functions at various sites to produce metabolic and physiologic changes, which alter, modulate and improve or reverse the basic abnormalities that are responsible for the development of various neurological diseases. As various aberrant pathways are integrated and interrelated to varying degrees and, hence functionally augment each other's pathologic effects, where (C1) is able to block this negative synergism. Also (C1) involves multilmodal neurofacilitatory approach, and involves a dietary approach designed to optimize glucose and insulin metabolism, a stress reduction program designed to down-regulate the hypothalamic-pituitary-adrenal axis (HPAA) and lower cortisol levels, and a cognitive retraining program.

Dwg.0/0

=> fil hom
FILE 'HOME' ENTERED AT 15:19:11 ON 29 JUL 2003